Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation: 2023-2024

Historic Share-based Compensation for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $11.4 million.

  • CG Oncology's Share-based Compensation rose 176.75% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 240.46%. This contributed to the annual value of $11.4 million for FY2024, which is 646.20% up from last year.
  • Latest data reveals that CG Oncology reported Share-based Compensation of $11.4 million as of FY2024, which was up 646.20% from $1.5 million recorded in FY2023.
  • CG Oncology's 5-year Share-based Compensation high stood at $11.4 million for FY2024, and its period low was $1.5 million during FY2023.
  • Over the past 2 years, CG Oncology's median Share-based Compensation value was $6.5 million (recorded in 2023), while the average stood at $6.5 million.
  • Data for CG Oncology's Share-based Compensation shows a peak YoY skyrocketed of 646.20% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows CG Oncology's Share-based Compensation stood at $1.5 million in 2023, then spiked by 646.20% to $11.4 million in 2024.